Levofloxacin Lactate Tablets

This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, and Gram-negative bacteria such as Haemophilus influenzae, Legionella pneumophila, and Neisseria gonorrhoeae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Mycoplasma pneumoniae and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. This product is the levorotatory form of ofloxacin, and its in vitro antibacterial activity is about twice that of ofloxacin. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.

Levofloxacin lactate.

This product is suitable for the following mild and moderate infections caused by sensitive bacteria: respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (nodal inflammation), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Oral. Common dosage for adults: 1. Bronchial infection and lung infection: 0.2g once, twice a day, or 0.1g once, 3 times a day, for a course of 7 to 14 days. 2. Acute simple lower urinary tract infection: 0.1g once, twice a day, for a course of 5 to 7 days; complicated urinary tract infection: 0.2g once, twice a day, or 0.1g once, 3 times a day, for a course of 10 to 14 days. 3. Bacterial prostatitis: 0.2g once, twice a day, for a course of 6 weeks. Common dosage for adults is 0.3 to 0.4g per day, divided into 2 to 3 times. If the infection is severe or the sensitivity of the pathogen is poor, such as Pseudomonas aeruginosa and other Pseudomonas bacterial infections, the therapeutic dose can be increased to 0.6g per day, divided into 3 times.

1. Gastrointestinal reactions: abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, skin itching, occasionally exudative erythema multiforme and angioneurotic edema. Photosensitivity reactions are less common. 4. Occasionally, the following may occur: ① epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors. ② interstitial nephritis manifestations such as hematuria, fever, and rash. ③ phlebitis. ④ crystalluria, which is more common when used in high doses. ⑤ joint pain. 5. A small number of patients may experience elevated serum aminotransferases, increased blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

1. Patients who are allergic to this product and fluoroquinolones are prohibited from using this product. 2. Children and adolescents under 18 years old should use it with caution. 3. Pregnant women are prohibited from using this product.

Precautions for children: Use with caution in children and adolescents under 18 years of age. Precautions for pregnancy and lactation: Do not use during pregnancy.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2β), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. This product has little effect on the metabolism of theophylline, but the blood concentration of theophylline should still be measured and the dosage adjusted when used in combination. 3. When this product is used in combination with cyclosporine, the blood concentration of cyclosporine can be increased. The blood concentration of cyclosporine must be monitored and the dosage adjusted. 4. When this product is used in combination with the anticoagulant warfarin, although the anticoagulant effect of the latter is slightly enhanced, the patient's prothrombin time should also be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increased blood concentration of this product. 6. This product can interfere with the metabolism of caffeine, thereby reducing the elimination of caffeine, prolonging the blood elimination half-life (t1/2β), and may cause central nervous system toxicity. 7. Antacids and iron preparations containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together. 8. When this product is used in combination with the non-steroidal anti-inflammatory drug fenbufen, convulsions occasionally occur, so it is not suitable for use with fenbufen. 9. This product may cause blood sugar disorders when used in combination with oral hypoglycemic drugs. Therefore, blood sugar concentrations should be monitored during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Keep away from light and store in sealed container.

0.1g (calculated as levofloxacin)

24 months.

Lanxiha Sanlian Pharmaceutical Co., Ltd.

• Founded in:

  2011-02-28

• Address:

  Middle section of Ha Sanlian Road, Lanxi Economic Development Zone, Lanxi County, Suihua City, Heilongjiang Province

• Tax NO.:

  91231222569852478D

• Registered Funds:

  440 million yuan

• Email:

  Log in to view